Whitepapers

Switching cryopreservation media between development and clinical manufacturing means revalidating freeze-thaw performance. This data sheet covers a low-viscosity freezing medium with 10% DMSO available in both RUO and GMP grades, so ... read more

The move from research-grade to GMP-grade reagents is where inconsistent sourcing, performance variability, and last-minute substitutions turn into failed tech transfers and regulatory delays. This white paper breaks down the RUO, RUO+, GMP... read more

When product purity is critical, particle generation matters. This application note evaluates visible and sub-visible particle levels during 24 hours of high-speed mixing under challenging temperature conditions. Results showed particle ... read more

Explore how targeted cell culture supplementation can enhance rAAV production. This application note highlights strategies to improve viral yield, sustain cell health, and optimize overall process performance. read more

Automation could cut cell therapy manufacturing costs while scaling treatment to more patients. Learn how automation and the use of robotics help patients with cell therapy accessibility by reducing processing time, lowering cost to ... read more

As cell therapy development advances toward broader patient access, manufacturing strategy increasingly determines scalability, cost, and commercial feasibility. Autologous models remain constrained by patient-specific production, complex ... read more